FDA Approves Simplified Monthly Injection for Lilly’s Omvoh in Ulcerative Colitis
Eli Lilly and Company has received U.S. Food and Drug Administration (FDA) approval for a new single-injection, once-monthly maintenance regimen of Omvoh (mirikizumab-mrkz) for adults with moderately to severely active ulcerative colitis (UC). The 200 mg/2 mL subcutaneous dose replaces the previous two-injection regimen, offering patients a more convenient treatment option starting in early 2026….
